Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies

Tumor Mutational
Burden (TMB)


Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.

ORDER NOW

What is Tumor Mutational Burden (TMB)?

Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.

Refers to the total number of somatic mutations that exist within a tumor’s genome.

A subset of these mutations may result in expressed proteins, termed neo-antigens, that are not recognized by the host’s immune system as self, and therefore have the potential to be immunogenic, leading to an anti-tumor immune-mediated response.

TMB Clinical Utility

Tumors with a high mutation burden may have a higher rate of neo-antigens which, in principle, would be expected to be more immunogenic than tumors with comparatively low mutation burden.

Technical Info

The test is performed using the Oncomine™ Tumor Mutation Load Assay (409 genes). It is a robust targeted NGS assay, that provides accurate quantitation of somatic mutations to assess tumor mutation burden, in formalin-fixed, paraffin-embedded (FFPE) tissues.

How to order

Our dedicated Client Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.

Please click here to see the specimen preparation and shipping instructions

If you would like to send us your sample,

contact us in order to arrange for all the logistics.

Please click here

Download Forms

you are already aware of the process of sending a sample, in order to download all the related forms.

Please click here
Change cookies consent Revoke cookies consent